

# Simona De Summa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2206556/publications.pdf>

Version: 2024-02-01

64  
papers

1,429  
citations

361296

20  
h-index

360920

35  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3515  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. <i>Diagnostics</i> , 2022, 12, 682.	1.3	2
2	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2227.	1.8	2
3	Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkin's Lymphoma Survivors. <i>Journal of Personalized Medicine</i> , 2021, 11, 215.	1.1	5
4	Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test. <i>Diagnostics</i> , 2021, 11, 975.	1.3	3
5	Molecular alterations in basal cell carcinoma subtypes. <i>Scientific Reports</i> , 2021, 11, 13206.	1.6	19
6	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 3567.	1.0	30
7	Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing. <i>Cancers</i> , 2021, 13, 4714.	1.7	3
8	A Promising Role of TGF- $\beta$ 2 Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1241.	0.8	3
9	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. <i>Cancers</i> , 2020, 12, 3380.	1.7	71
10	Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 590707.	1.3	14
11	P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. <i>Cell Death and Disease</i> , 2020, 11, 748.	2.7	27
12	Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study. <i>Frontiers in Genetics</i> , 2020, 11, 641.	1.1	71
13	miRNAs as Key Players in the Management of Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 415.	1.8	23
14	Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19152.	2.1	20
15	Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. <i>Oncology Letters</i> , 2020, 20, 2469-2476.	0.8	3
16	Standardization of CTC AR $\beta$ 7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. <i>Prostate</i> , 2019, 79, 54-61.	1.2	20
17	KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy. <i>Cancers</i> , 2019, 11, 1145.	1.7	33
18	Exhaled breath condensate biomarkers for lung cancer. <i>Journal of Breath Research</i> , 2019, 13, 044002.	1.5	41

#	ARTICLE	IF	CITATIONS
19	BRCA germline mutation test for all woman with ovarian cancer?. BMC Cancer, 2019, 19, 641.	1.1	9
20	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942.	1.7	66
21	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 2019, 11, 749.	1.7	4
22	P1.04-58 Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell. Journal of Thoracic Oncology, 2019, 14, S463-S464.	0.5	0
23	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 453-461.	1.5	15
24	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Biology of Blood and Marrow Transplantation, 2018, 24, 608-613.	2.0	19
25	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Annals of Oncology, 2018, 29, 2363-2370.	0.6	89
26	Improvable Lifestyle Factors in Lymphoma Survivors. Acta Haematologica, 2018, 139, 235-237.	0.7	7
27	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer, 2018, 18, 552.	1.1	14
28	Comment on "Renewed interest in the progesterone receptor in breast cancer". British Journal of Cancer, 2017, 117, e1-e1.	2.9	3
29	GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data. BMC Bioinformatics, 2017, 18, 119.	1.2	79
30	VEGF and TWIST1 in a 16â€biomarker immunoprofile useful for prognosis of breast cancer patients. International Journal of Cancer, 2017, 141, 1901-1911.	2.3	10
31	u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer, 2017, 17, 215.	1.1	20
32	Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients. Oncology Letters, 2017, 14, 4384-4390.	0.8	2
33	Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a caucasian family. Oncotarget, 2017, 8, 29751-29759.	0.8	8
34	TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget, 2017, 8, 50715-50723.	0.8	20
35	Adipokines in hereditary breast cancer patients and healthy relatives. Oncotarget, 2017, 8, 101255-101261.	0.8	5
36	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Next-generation sequencing: advances and applications in cancer diagnosis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7355-7365.	1.0	142
38	BRCA1 diagnostic workflow from next-generation sequencing technologies to variant identification and final report. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 803-813.	1.5	11
39	40P A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center. <i>Journal of Thoracic Oncology</i> , 2016, 11, S72.	0.5	0
40	Nuclear PARP1 expression and its prognostic significance in breast cancer patients. <i>Tumor Biology</i> , 2016, 37, 6143-6153.	0.8	32
41	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , 2016, 17, 400-406.	1.5	67
42	miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. <i>Tumor Biology</i> , 2016, 37, 5503-5513.	0.8	16
43	miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. <i>Oncotarget</i> , 2016, 7, 80363-80372.	0.8	21
44	Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation. <i>Annals of Oncology</i> , 2015, 26, vi26.	0.6	0
45	MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. <i>Oncotarget</i> , 2015, 6, 471-483.	0.8	51
46	MiRNAs modulate gastric cancer drug response by affecting hypoxia signaling. <i>Annals of Oncology</i> , 2015, 26, vi99.	0.6	0
47	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1027-1035.	1.5	27
48	Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants. <i>Archives of Dermatological Research</i> , 2015, 307, 495-503.	1.1	18
49	Immunoprofile from tissue microarrays to stratify familial breast cancer patients. <i>Oncotarget</i> , 2015, 6, 27865-27879.	0.8	5
50	Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. <i>Cell Death and Disease</i> , 2014, 5, e1076-e1076.	2.7	17
51	Genetic risk transmission in a family affected by familial breast cancer. <i>Journal of Human Genetics</i> , 2014, 59, 51-53.	1.1	4
52	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. <i>PLoS ONE</i> , 2014, 9, e112025.	1.1	15
53	Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. <i>Journal of Translational Medicine</i> , 2014, 12, 319.	1.8	9
54	MicroRNA expression profiling in male and female familial breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 2361-2368.	2.9	16

#	ARTICLE	IF	CITATIONS
55	444: Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. <i>European Journal of Cancer</i> , 2014, 50, S107.	1.3	0
56	The value of new high-throughput technologies for diagnosis and prognosis in solid tumors. <i>Cancer Biomarkers</i> , 2014, 14, 103-117.	0.8	15
57	DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer. <i>Current Molecular Medicine</i> , 2014, 14, 45-57.	0.6	14
58	BRCAness: a deeper insight into basal-like breast tumors. <i>Annals of Oncology</i> , 2013, 24, viii13-viii21.	0.6	54
59	HOX gene methylation status analysis in patients with hereditary breast cancer. <i>Journal of Human Genetics</i> , 2013, 58, 51-53.	1.1	30
60	BRCA Unclassified Variants: How Can They be Classified?. <i>Current Women's Health Reviews</i> , 2012, 8, 30-37.	0.1	1
61	DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families. <i>Molecular Biotechnology</i> , 2012, 52, 8-15.	1.3	22
62	Unclassified variants in BRCA genes: guidelines for interpretation. <i>Annals of Oncology</i> , 2011, 22, i18-i23.	0.6	50
63	Innovative technology for cancer risk analysis. <i>Annals of Oncology</i> , 2011, 22, i37-i43.	0.6	2
64	Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 875-878.	1.1	11